Epidemiological study of epNEC and LCNEC-L patients in Japan using the MASTER KEY Registry

Epidemiological study of epNEC and LCNEC-L patients in Japan using the MASTER KEY Registry - NEC patients in Japan (MASTER KEY Registry)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059606

Enrollment

Registered

2025-10-31

Start date

2025-08-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extra-pulmonary neuroendocrine carcinoma (epNEC) and large cell neuroendocrine carcinoma of the lung (LCNEC-L)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who gave a written consent to the MASTER KEY Registry (NCCH1612) and were enrolled in it 2) Clinical diagnosis of epNEC or LCNEC-L 3) Patients with any records of pharmacotherapy

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
A) Patient demographics, clinical characteristics and biomarkers B) Treatment status at each LOP C) Treatment outcomes by each LOP - rwORR - rwDCR - rwOS - rwPFS - rwTTNT	—

Secondary

Measure	Time frame
- DLL3 expression status - Treatment outcomes by DLL3 expression status	—

Countries

Japan

Contacts

Public ContactHana Kimura

Nippon Boehringer Ingelheim Co., Ltd Real World Evidence Japan

hana.kimura@boehringer-ingelheim.com070-2674-6485

Outcome results